Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/35846
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | BUZO, Bruno Fernando | |
dc.contributor.author | RAMOS, Jessica Fernandes | |
dc.contributor.author | ROSSETTI, Renata Ariza Marques | |
dc.contributor.author | SALLES, Nanci | |
dc.contributor.author | MEDRONE-JUNIOR, Alfredo | |
dc.contributor.author | ROCHA, Vanderson | |
dc.contributor.author | NASTRI, Ana Catharina de Seixas Santos | |
dc.date.accessioned | 2020-06-01T14:46:41Z | |
dc.date.available | 2020-06-01T14:46:41Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | TRANSPLANT INFECTIOUS DISEASE, v.22, n.2, article ID e13243, 9p, 2020 | |
dc.identifier.issn | 1398-2273 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/35846 | |
dc.description.abstract | Background Hepatitis B virus (HBV) infection is a worldwide concern with a broad distribution. In immunosuppressed populations, such as solid organ and hematopoietic stem cell transplant (HSCT) recipients, it can reactivate leading to acute hepatic failure. Different risk factors are known for higher rates of reactivation, and entecavir, tenofovir, and lamivudine are often used for prophylaxis and treatment. However, data regarding the impact of antiviral drugs in neutrophil and platelet engraftment are still unknown and concern the management of viral hepatitis post-HSCT. Methods We performed a single-center, retrospective, observational study reviewing medical records of patients referred for hematopoietic stem cell transplant from 2010 to 2017, which were also HBV infected, aiming to describe outcomes related to antiviral treatment and also the impact on platelet and neutrophil recovery after transplant. A secondary goal consisted of analyzing the impact of HBV infection in early and late mortality post-HSCT. The study included patients with positive blood bank screening for hepatitis B infection (HBsAg, Anti-HBc or HBV-NAT), confirmed later on by a laboratory routine serology. Results A total of 1132 hematopoietic stem cell recipients were assessed between 2010 and 2017. Eighty-six patients were confirmed to have HBV infection, of which six were HBsAg-positive, 20 were isolated anti-HBc-positive, and 60 had resolved infection (anti-HBc-positive and anti-HBs-positive). With regard to prophylaxis, 19 patients underwent HSCT on HBV antiviral therapy or prophylaxis: two were HBeAg-positive, three were HBeAg-negative and HBV-DNA was only detectable in three of them. Moreover, one patient had an occult HBV infection. Regarding therapy, 9 patients were on entecavir, 6 patients on lamivudine, two on tenofovir, and two of them on a combination of tenofovir + lamivudine due to HIV co-infection. Reverse seroconversion was not identified in any patients receiving antiviral therapy or prophylaxis, but it was detected in one patient with occult hepatitis B and another with resolved infection. No severe side effects led to therapy discontinuation in the treated group, which also did not have any significant delay in neutrophil or platelet engraftment when compared to patients without antiviral therapy. In addition, the only factors associated with increased mortality were transplant onset after 50 years, allogeneic transplant and myeloablative conditioning regimens. Interestingly, the presence of HBsAg or detectable HBV-DNA was not related to worse outcomes, neither the use of rituximab. In multivariate analysis, the use of antiviral therapy, the occurrence of graft-versus-host disease or CMV reactivation also was not linked to increased mortality. Conclusions To sum up, HBV serology, ALT, and HBV-DNA monitoring are essential to detect hepatic flares earlier, even in populations with chronic inactive hepatitis, due to the possibility of later seroconversion. HBV infection was not related to increased 2-year mortality post-transplant. Antiviral prophylaxis did not cause any important clinical or laboratory side effects that could demand discontinuation, and its use was not associated with later neutrophil and platelet engraftments. | eng |
dc.language.iso | eng | |
dc.publisher | WILEY | eng |
dc.relation.ispartof | Transplant Infectious Disease | |
dc.rights | restrictedAccess | eng |
dc.subject | antiviral therapy | eng |
dc.subject | bone marrow transplant | eng |
dc.subject | hematopoietic stem cell transplant | eng |
dc.subject | hepatitis B | eng |
dc.subject | neutrophil engraftment | eng |
dc.subject | platelet engraftment | eng |
dc.subject | reactivation | eng |
dc.subject.other | core-positive donors | eng |
dc.subject.other | liver-transplantation | eng |
dc.subject.other | hbv reactivation | eng |
dc.subject.other | prevention | eng |
dc.subject.other | lamivudine | eng |
dc.subject.other | infection | eng |
dc.subject.other | therapy | eng |
dc.subject.other | risk | eng |
dc.subject.other | prophylaxis | eng |
dc.subject.other | guidelines | eng |
dc.title | Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center | eng |
dc.type | article | eng |
dc.rights.holder | Copyright WILEY | eng |
dc.identifier.doi | 10.1111/tid.13243 | |
dc.identifier.pmid | 31901206 | |
dc.subject.wos | Immunology | eng |
dc.subject.wos | Infectious Diseases | eng |
dc.subject.wos | Transplantation | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | SALLES, Nanci:Hosp Clin HCFMUSP, Fundacao Prosangue, Sao Paulo, Brazil | |
hcfmusp.description.articlenumber | e13243 | |
hcfmusp.description.issue | 2 | |
hcfmusp.description.volume | 22 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000506876200001 | |
hcfmusp.origem.id | 2-s2.0-85077862612 | |
hcfmusp.publisher.city | HOBOKEN | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Anastasiou Olympia E, 2017, Hepatol Commun, V1, P1014, DOI 10.1002/hep4.1118 | eng |
hcfmusp.relation.reference | Bohorquez HE, 2013, LIVER TRANSPLANT, V19, P611, DOI 10.1002/lt.23644 | eng |
hcfmusp.relation.reference | Cholongitas E, 2010, J HEPATOL, V52, P272, DOI 10.1016/j.jhep.2009.11.009 | eng |
hcfmusp.relation.reference | De Feo TM, 2005, TRANSPL P, V37, P1238, DOI 10.1016/j.transproceed.2004.12.041 | eng |
hcfmusp.relation.reference | Mello FCD, 2012, MEM I OSWALDO CRUZ, V107, P317, DOI 10.1590/S0074-02762012000300005 | eng |
hcfmusp.relation.reference | European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021 | eng |
hcfmusp.relation.reference | Hilgendorf I, 2011, BONE MARROW TRANSPL, V46, P1274, DOI 10.1038/bmt.2010.290 | eng |
hcfmusp.relation.reference | Hoofnagle JH, 2009, HEPATOLOGY, V49, pS156, DOI 10.1002/hep.22945 | eng |
hcfmusp.relation.reference | Huprikar S, 2015, AM J TRANSPLANT, V15, P1162, DOI 10.1111/ajt.13187 | eng |
hcfmusp.relation.reference | Kitano K, 2006, EUR J HAEMATOL, V77, P255, DOI 10.1111/j.1600-0609.2006.00678.x | eng |
hcfmusp.relation.reference | Knoll A, 2004, BONE MARROW TRANSPL, V33, P925, DOI 10.1038/sj.bmt.1704457 | eng |
hcfmusp.relation.reference | Kusumoto S, 2015, CLIN INFECT DIS, V61, P719, DOI 10.1093/cid/civ344 | eng |
hcfmusp.relation.reference | Onozawa M, 2008, BIOL BLOOD MARROW TR, V14, P1226, DOI 10.1016/j.bbmt.2008.08.007 | eng |
hcfmusp.relation.reference | Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116 | eng |
hcfmusp.relation.reference | Ouseph R, 2010, TRANSPLANT REV-ORLAN, V24, P167, DOI 10.1016/j.trre.2010.05.001 | eng |
hcfmusp.relation.reference | Pereira GFM, 2011, B EPIDEMIOLOGICO HEP, V1, P21 | eng |
hcfmusp.relation.reference | Pilmore HL, 2012, TRANSPLANTATION, V94, P205, DOI 10.1097/TP.0b013e31824e3db4 | eng |
hcfmusp.relation.reference | Raimondo G, 2007, J HEPATOL, V46, P160, DOI 10.1016/j.jhep.2006.10.007 | eng |
hcfmusp.relation.reference | Reddy KR, 2015, GASTROENTEROLOGY, V148, P215, DOI 10.1053/j.gastro.2014.10.039 | eng |
hcfmusp.relation.reference | Sarmati L, 2017, CLIN MICROBIOL INFEC, V23, P935, DOI 10.1016/j.cmi.2017.06.023 | eng |
hcfmusp.relation.reference | Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X | eng |
hcfmusp.relation.reference | Shang J, 2016, BONE MARROW TRANSPL, V51, P581, DOI 10.1038/bmt.2015.328 | eng |
hcfmusp.relation.reference | Shouval D, 2013, SEMIN LIVER DIS, V33, P167, DOI 10.1055/s-0033-1345722 | eng |
hcfmusp.relation.reference | Siyahian A, 2018, BIOL BLOOD MARROW TR, V24, P1483, DOI 10.1016/j.bbmt.2018.02.027 | eng |
hcfmusp.relation.reference | Skagen CL, 2011, CLIN TRANSPLANT, V25, pE243, DOI 10.1111/j.1399-0012.2011.01409.x | eng |
hcfmusp.relation.reference | Terrault Norah A, 2018, Clin Liver Dis (Hoboken), V12, P33, DOI 10.1002/cld.728 | eng |
hcfmusp.relation.reference | Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019 | eng |
hcfmusp.relation.reference | Torres HA, 2012, NAT REV CLIN ONCOL, V9, P156, DOI 10.1038/nrclinonc.2012.1 | eng |
hcfmusp.relation.reference | Vento S, 2002, LANCET ONCOL, V3, P333, DOI 10.1016/S1470-2045(02)00773-8 | eng |
hcfmusp.relation.reference | Yen RD, 2006, AM J TRANSPLANT, V6, P1077, DOI 10.1111/j.1600-6143.2006.01313.x | eng |
hcfmusp.relation.reference | Zappulo E, 2019, INFECTION, V47, P59, DOI 10.1007/s15010-018-1214-5 | eng |
hcfmusp.relation.reference | Zurawska U, 2012, J CLIN ONCOL, V30, P3167, DOI 10.1200/JCO.2011.40.7510 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1399-3062 | |
hcfmusp.citation.scopus | 2 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - IMT Artigos e Materiais de Revistas Científicas - LIM/31 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_BUZO_Hepatitis_B_virus_among_hematopoietic_stem_cell_transplant_2020.PDF Restricted Access | publishedVersion (English) | 560.98 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.